Legal & General Group Plc reduced its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 20.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,875,062 shares of the medical instruments supplier's stock after selling 478,219 shares during the period. Legal & General Group Plc owned about 0.65% of Becton, Dickinson and Company worth $425,395,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Principal Financial Group Inc. raised its position in Becton, Dickinson and Company by 1.5% during the third quarter. Principal Financial Group Inc. now owns 1,179,715 shares of the medical instruments supplier's stock valued at $284,429,000 after buying an additional 16,918 shares during the period. Janus Henderson Group PLC grew its position in Becton, Dickinson and Company by 4.2% during the third quarter. Janus Henderson Group PLC now owns 45,947 shares of the medical instruments supplier's stock valued at $11,077,000 after purchasing an additional 1,843 shares in the last quarter. Integrated Wealth Concepts LLC lifted its position in Becton, Dickinson and Company by 75.3% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 4,730 shares of the medical instruments supplier's stock worth $1,140,000 after buying an additional 2,031 shares in the last quarter. Quantinno Capital Management LP grew its holdings in shares of Becton, Dickinson and Company by 26.3% during the 3rd quarter. Quantinno Capital Management LP now owns 7,690 shares of the medical instruments supplier's stock valued at $1,854,000 after acquiring an additional 1,599 shares in the last quarter. Finally, MML Investors Services LLC raised its holdings in shares of Becton, Dickinson and Company by 51.8% during the third quarter. MML Investors Services LLC now owns 62,762 shares of the medical instruments supplier's stock worth $15,132,000 after acquiring an additional 21,427 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company's stock.
Analyst Ratings Changes
Several equities research analysts recently commented on BDX shares. StockNews.com raised Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Wednesday, April 2nd. Piper Sandler lifted their price objective on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an "overweight" rating in a research note on Tuesday, January 28th. Finally, Barclays cut their target price on Becton, Dickinson and Company from $279.00 to $261.00 and set an "overweight" rating on the stock in a report on Monday, April 7th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $275.71.
Get Our Latest Stock Report on Becton, Dickinson and Company
Becton, Dickinson and Company Stock Performance
BDX traded up $2.42 during trading on Friday, hitting $201.54. The stock had a trading volume of 1,850,652 shares, compared to its average volume of 1,688,275. The firm has a market cap of $57.87 billion, a PE ratio of 33.48, a P/E/G ratio of 1.63 and a beta of 0.35. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 12 month low of $193.03 and a 12 month high of $251.99. The company has a 50 day simple moving average of $223.97 and a 200-day simple moving average of $229.81.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, topping analysts' consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. Analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.
Becton, Dickinson and Company Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Monday, March 31st. Stockholders of record on Monday, March 10th were paid a $1.04 dividend. The ex-dividend date of this dividend was Monday, March 10th. This represents a $4.16 annualized dividend and a dividend yield of 2.06%. Becton, Dickinson and Company's payout ratio is 69.10%.
Becton, Dickinson and Company announced that its Board of Directors has initiated a stock buyback plan on Tuesday, January 28th that allows the company to repurchase 10,000,000 outstanding shares. This repurchase authorization allows the medical instruments supplier to reacquire shares of its stock through open market purchases. Shares repurchase plans are often a sign that the company's board of directors believes its stock is undervalued.
Insider Buying and Selling
In related news, EVP Michael David Garrison sold 479 shares of the stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $197.28, for a total value of $94,497.12. Following the completion of the sale, the executive vice president now owns 4,887 shares in the company, valued at approximately $964,107.36. This trade represents a 8.93 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Richard Byrd sold 459 shares of the business's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $230.00, for a total value of $105,570.00. Following the transaction, the executive vice president now owns 6,952 shares in the company, valued at $1,598,960. This represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 4,675 shares of company stock valued at $1,057,182. 0.36% of the stock is owned by company insiders.
Becton, Dickinson and Company Company Profile
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Featured Articles
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
